Histologic diagnosis in young women with breast cancer

Andreu, Francisco Javier

doi:10.1007/s10549-010-1060-3

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When setting Luminal A as a baseline, the HR value of triple-negative subtype (HR = 2.90) remains larger than that of Luminal B (HR = 2.23) or Her-2 subtypes (HR = 2.26) for overall recurrence (Table 4). Previous studies have shown that triple-negative receptor status is strongly associated with poor clinical outcomes [56], and that young women more frequently suffer from triple-negative tumors [57]. Thus, triple-negative subtype should be considered the biggest risk factor for recurrence and adjuvant CT should be administered in BCT.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of molecular subtyping in predicting postoperative recurrence in breast-conserving therapy: a 15-study meta-analysis

et al. 2014

View full text Add to dashboard Cite

BackgroundRecent research displays that breast cancer (BC) is a heterogeneous disease and distinct molecular subtypes yield different prognostic outcomes.MethodsWe conducted a meta-analysis to clarify the role of molecular subtypes in recurrence risk after breast-conserving therapy (BCT). Eligible studies of single- (ER, PR, Her-2, and p53) and triple-molecular (Luminal A, Luminal B, Her-2, triple-negative) subtypes were identified through multiple search strategies. Pooled hazard ratios with 95% confidence intervals were calculated to assess this research topic.ResultsFifteen studies involving 21,645 participants were included in the meta-analysis. Her-2 positive patients had a significantly higher recurrence risk in both overall merge (HR = 1.97, 95% CI: 1.41-2.75) and subtotal merge of local recurrence (LR) (HR = 1.93, 95% CI: 1.34-2.78). Significantly higher risk of recurrence was also observed in p53 positive patients by overall merge (HR = 1.78, 95% CI: 1.49 -2.12) and subtotal merge of LR (HR = 1.73, 95% CI: 1.44-2.07). When setting Luminal A as a baseline, Luminal B, Her-2, and triple-negative all showed significantly increased risk for both LR and distant recurrence (DR). Comparing triple-negative and non-triple-negative subtypes showed the biggest risk for overall recurrence (HR = 3.19, 95% CI: 1.91-5.31) and LR (HR = 3.31, 95% CI: 1.69-6.45).ConclusionsOur meta-analysis showed significant differences in recurrence risk among various molecular subtypes after BCT. Although Her-2 and p53 positive subtypes can be considered independent prognostic biomarkers for indicating high LR risk, triple-molecular biomarkers showed higher clinical value. Triple-negative subtype showed the highest recurrence risk among all subtypes, and adjuvant chemotherapy should be considered for it.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy of molecular subtyping in predicting postoperative recurrence in breast-conserving therapy: a 15-study meta-analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Triple negative receptor status is strongly associated with poor clinical outcome [19,20]. In general, young women have more frequently triple negative tumours [19,21]. This could therefore be the biological explanation for worse outcome related to young age [7][8][9][10]13,16].…”

Section: Mcdonald Et Al Recently Reported On a Series Of 282 Invasivmentioning

confidence: 99%

Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: Results on local control and survival

Bantema-Joppe

Laan

Bock

et al. 2011

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Este subtipo, al igual que el subtipo basaloide, se ha descrito como asociado a un mal pronóstico [25]. Minoritariamente, un 5,56% (n=4) de los Epidemiológicamente, la prevalencia de los subtipos inmunohistoquímicos en pacientes jóvenes varía entre estudios [28]. Resulta interesante comparar que en un estudio realizado por Ihemelandu, C. et al en el cual se evaluó un grupo de mujeres menores de 50 años, el porcentaje de pacientes que presentó un carcinoma de tipo Luminal A fue de 50%; mientras que 21% expresaba el subtipo basal-like [29].…”

Section: Subtipo Inmunohistoquímicounclassified

Cáncer de mama en mujeres jóvenes características clínicas y patológicas

2010

View full text Add to dashboard Cite

Resumen:El presente estudio tiene como objetivo caracterizar los carcinomas invasores de la glándula mamaria de una cohorte de 72 mujeres menores de 50 años, diagnosticadas durante el año 2006 en un centro de salud capitalino de atención terciaria en Costa Rica. Se investigaron los marcadores biológicos: edad, tipo histológico, receptores hormonales [RE, RP y HER2], grado histológico, diámetro y estadio de los ganglios axilares. Se encontró una predominancia de carcinomas del tipo ductal infiltrante (84,85%, n=56), de grado histológico alto (86,00% n=43), con tamaño mayor o igual a los 2cm (73,21% n=41), estadio de ganglios negativos (59,09% n=26) y de subtipo inmunohistoquímico Luminal A (48,61% n=35). Entre otros hallazgos, se encontró una frecuencia del 22,22% (n=16) de carcinomas triple negativos, de 7,57% (n=5) del tipo histológico lobulillar y 4,45% (n=3) del tipo medular.Palabras clave: Cáncer de mama, edad, inmunohistoquímica, Receptor de Estrógeno, Receptor de Progesterona, HER-2. Abstract:The aim of this study is to characterize breast invasive carcinomas in a cohort of 72 women under 50 years of age diagnosed through 2006 in a tertiary health care facility in Costa Rica. We analyzed biological biomarkers: age, histological type, hormone receptors [ER, PR and HER2], histological grade, tumor diameter and axillary lymph 54

show abstract

Histologic diagnosis in young women with breast cancer

Cited by 4 publications

References 22 publications

The efficacy of molecular subtyping in predicting postoperative recurrence in breast-conserving therapy: a 15-study meta-analysis

The efficacy of molecular subtyping in predicting postoperative recurrence in breast-conserving therapy: a 15-study meta-analysis

Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: Results on local control and survival

Cáncer de mama en mujeres jóvenes características clínicas y patológicas

Contact Info

Product

Resources

About